You are now leaving www.klisyrihcp.com

You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.

OK

5-day topical treatment for AK

Available in convenient, disposable, single-use packs

Klisyri single use packages

*

Eligible patients with commercial (nongovernment) insurance only. Terms and conditions may apply.
AK: actinic keratosis.

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

References:

1.
Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused Update: Guidelines of care for the management of actinic keratosis. JAAD. 2022. doi: https://doi.org/10.1016/ j.jaad.2022.04.013 2. KLISYRI® [package insert]. Malvern, PA: Almirall, LLC, 2021.

Almirall logo

This site is intended for US audiences only.

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023

Klisyri logo

Sign Up

Information Request

Qualified U.S. healthcare professionals who are practicing medicine in the U.S. are invited to register, should they wish to receive information about KLISYRI®.

Terms and Conditions

Your submission of this Information Request form constitutes your specific request to receive ongoing email communications, including marketing communications and messages, from KLISYRI® and Almirall, LLC. You may opt out from such email communication at any time by following the "Unsubscribe" link and/or instructions included in the confirmation email you will receive as a result of this request.

By submission of this form, you affirm that you are a licensed healthcare professional eligible to practice in at least one state in the U.S. By submission of this form, you further agree to the terms and conditions set forth in the Almirall, LLC Privacy Policy page, available by clicking on the link at the bottom of this page.

*Required fields.
Submitting...

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2023. All Rights Reserved. Almirall, LLC, 101 Lindenwood Drive, Suite 200, Malvern, PA 19355 US-TIRBA-2300013 03/2023

Klisyri logo

Thank You For Signing Up!

You are now enrolled to receive news and updates about KLISYRI® (tirbanibulin) ointment. Please look for a welcome email that will be sent to .